Mylan Strikes €642m Deal For Aspen’s Thrombosis Business In Europe
Diversifies Mylan Further Ahead Of Viatris
Executive Summary
With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.
You may also be interested in...
Aspen Explains U-Turn On Withdrawing From Proposed API Sale
Following years of reshaping its operations, one part of Aspen Pharmacare’s business that is to stay for now is the firm’s API division. The South African firm’s management explained why as Aspen presented results from its financial first half, hours after wrapping up a key COVID-19 licensing deal with Johnson & Johnson.
Rovi Remains ‘Bullish’ On Enoxaparin Biosimilar With Much Room To Grow
Spain’s Laboratorios Farmaceuticos Rovi has set out why it remains confident in its prospects for its Becat (enoxaparin) biosimilar to Sanofi’s Lovenox/Clexane while providing an update for the firm’s Doria once-a-month injectable formulation of risperidone.
Aspen Confirms ‘Material’ Offers For API Unit Remain Under Consideration
Aspen Pharmacare is continuing to ponder offloading another part of its operations, with bids under consideration for its significant API business units. The company only recently sold a basket of products in South Africa to Acino.